Wells Fargo analyst Yanan Zhu maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) yesterday and set a price target of $77.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yanan Zhu has given his Buy rating due to a combination of factors including the promising developments in Ionis Pharmaceuticals’ drug pipeline. The positive outlook on olezarsen for severe hypertriglyceridemia (sHTG) is a significant factor, as it offers a convenient monthly dosing schedule that is likely to improve patient compliance compared to existing therapies. Additionally, the efficacy of olezarsen in lowering triglyceride levels is comparable to other treatments, which is crucial given that current options do not achieve ideal triglyceride reduction in all patients.
Another key factor contributing to the Buy rating is the optimism surrounding the HORIZON study for lowering lipoprotein(a) [Lp(a)], which is expected to reduce cardiovascular risk. The delay in the HORIZON readout is perceived positively, as it may result from improved LDL-C management, leading to lower event rates. These developments, combined with the potential market impact of these therapies, support a favorable outlook for Ionis Pharmaceuticals, justifying the Buy recommendation.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $59.00 price target.